Synaptogenix Ownership
| SNPX Stock | USD 2.86 0.06 2.14% |
Shares in Circulation | First Issued 2019-09-30 | Previous Quarter 1.2 M | Current Value 1.3 M | Avarage Shares Outstanding 4.2 M | Quarterly Volatility 3 M |
Synaptogenix |
Synaptogenix Stock Ownership Analysis
The company has price-to-book ratio of 0.3. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Synaptogenix recorded earning per share (EPS) of 10.27. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 5th of April 2024. Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company was incorporated in 2012 and is headquartered in New York, New York. Synaptogenix operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people. To find out more about Synaptogenix contact MBA MD at 973 242 0005 or learn more at https://www.synaptogen.com.Besides selling stocks to institutional investors, Synaptogenix also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Synaptogenix's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Synaptogenix's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Synaptogenix Quarterly Liabilities And Stockholders Equity |
|
Only 1.94% of Synaptogenix are currently held by insiders. Unlike Synaptogenix's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Synaptogenix's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Synaptogenix's insider trades
Synaptogenix Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Synaptogenix is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Synaptogenix backward and forwards among themselves. Synaptogenix's institutional investor refers to the entity that pools money to purchase Synaptogenix's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 10.8 K | Ubs Group Ag | 2024-12-31 | 3.2 K | Tower Research Capital Llc | 2024-12-31 | 266 | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 90.0 | Advisor Group Holdings, Inc. | 2024-12-31 | 34.0 | Blackrock Inc | 2024-12-31 | 29.0 | Bank Of America Corp | 2024-12-31 | 10.0 | 1832 Asset Management L.p | 2024-09-30 | 0.0 |
Synaptogenix Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Synaptogenix insiders, such as employees or executives, is commonly permitted as long as it does not rely on Synaptogenix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Synaptogenix insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Synaptogenix Outstanding Bonds
Synaptogenix issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Synaptogenix uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Synaptogenix bonds can be classified according to their maturity, which is the date when Synaptogenix has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| SNV 5625 15 FEB 28 Corp BondUS87164DVJ61 | View | |
| SYNCHRONY FINL 45 Corp BondUS87165BAG86 | View | |
| SYNCHRONY FINL 395 Corp BondUS87165BAM54 | View | |
| SYNCHRONY FINL 37 Corp BondUS87165BAL71 | View | |
| SYF 4875 13 JUN 25 Corp BondUS87165BAS25 | View | |
| SYF 2875 28 OCT 31 Corp BondUS87165BAR42 | View | |
| SYF 725 02 FEB 33 Corp BondUS87165BAU70 | View | |
| SNX 265 09 AUG 31 Corp BondUS87162WAK62 | View |
Synaptogenix Corporate Filings
8K | 20th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 20th of November 2024 Other Reports | ViewVerify | |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 7th of November 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Synaptogenix Stock Analysis
When running Synaptogenix's price analysis, check to measure Synaptogenix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synaptogenix is operating at the current time. Most of Synaptogenix's value examination focuses on studying past and present price action to predict the probability of Synaptogenix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synaptogenix's price. Additionally, you may evaluate how the addition of Synaptogenix to your portfolios can decrease your overall portfolio volatility.